Cochrane · systematic review · CD011441
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Chai‐Adisaksopha, C, Nevitt, SJ, Simpson, ML, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
9
No studies
2
Included studies
NR
No studies 2 · 16.7%Ungraded 1 · 8.3%Very low 0 · 0%Low 4 · 33.3%Moderate 5 · 41.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Prophylaxis therapy compared with on‐demand therapy with FEIBA for hemophilia A or B with inhibitors
Population: adults and children with hemophilia A or B with inhibitors
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall bleeding rates: total number of bleeding events Prophylaxis therapy vs on‐demand therapy with FEIBA | no estimate extracted | 1 study · 26 participants | Low Downgraded: risk of bias, imprecision |
Annualised bleeding rate Prophylaxis therapy vs on‐demand therapy with FEIBA | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: risk of bias, imprecision |
Target joint bleeding rate: number of hemarthrosis Prophylaxis therapy vs on‐demand therapy with FEIBA | no estimate extracted | 1 study · 26 participants | Low Downgraded: risk of bias, imprecision |
AJBR Prophylaxis therapy vs on‐demand therapy with FEIBA | no estimate extracted | 1 study · 34 participants | Moderate Downgraded: risk of bias, imprecision |
Quality of life Prophylaxis therapy vs on‐demand therapy with FEIBA | no estimate extracted | 2 studies · 58 participants | Low Downgraded: risk of bias, imprecision |
Safety of bypassing agents Prophylaxis therapy vs on‐demand therapy with FEIBA | no estimate extracted | 2 studies · 67 participants | Low Downgraded: risk of bias, imprecision |
High‐dose compared with low‐dose rFVIIa for hemophilia A or B with inhibitors
Population: adults and children with hemophilia A or B with inhibitors
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall bleeding rates: number of bleeds per month High‐dose vs low‐dose rFVIIa | no estimate extracted | 1 study · 22 participants | Moderate Downgraded: imprecision |
Annualised bleeding rate High‐dose vs low‐dose rFVIIa | no estimate extracted | 1 study · 24 participants | Ungraded |
Target joint bleeding rate High‐dose vs low‐dose rFVIIa | no estimate extracted | 1 study · 22 participants | Moderate Downgraded: imprecision |
AJBR High‐dose vs low‐dose rFVIIa | no estimate extracted | NR | No studies |
Quality of life High‐dose vs low‐dose rFVIIa | no estimate extracted | NR | No studies |
Safety of bypassing agents High‐dose vs low‐dose rFVIIa | no estimate extracted | 2 studies · 46 participants | Moderate Downgraded: imprecision |